New therapeutic approaches in the treatment of diabetic keratopathy: A review

Clinical and Experimental Ophthalmology

Volumn 39, Issue 3, 2011, Pages 259-270

  Abdelkader, Hamdy ^a   Patel, Dipika V ^b   Mcghee, Charles Nj ^a   Alany, Raid G ^a,c  

^a School of Pharmacy   (New Zealand)

^b THE UNIVERSITY OF AUCKLAND   (New Zealand)

^c KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Diabetic keratopathy; Growth factor; Insulin; Naltrexone; Nicergoline

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; BENZALKONIUM CHLORIDE; EDETATE CALCIUM DISODIUM; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; INSULIN; KERATINOCYTE GROWTH FACTOR; NALTREXONE; NERVE GROWTH FACTOR; NICERGOLINE; OPIOID GROWTH FACTOR; RISARESTAT; SCATTER FACTOR; SOMATOMEDIN C; SORBINIL; SUBSTANCE P; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CORNEA EPITHELIUM; CORNEA ULCER; DIABETES MELLITUS; DIABETIC KERATOPATHY; DRUG MECHANISM; DRUG TRANSPORT; EPITHELIZATION; HUMAN; KERATOPATHY; NONHUMAN; REVIEW; WOUND HEALING;

ANIMALS; CORNEA; CORNEAL DISEASES; DIABETES COMPLICATIONS; EPITHELIUM, CORNEAL; HUMANS; INSULIN; NALTREXONE; NERVE GROWTH FACTORS; NICERGOLINE; TRIGEMINAL GANGLION; WOUND HEALING;

EID: 79954515223     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2010.02435.x     Document Type: Review

References (119)

1. Gobbels M, Spitznas M, Oldendoerp J. Impairment of corneal epithelial barrier function in diabetics. Graefes Arch Clin Exp Ophthalmol 1989; 227: 142-4.
2. Lambiase A, Rama P, Aloe L, Bonini S. Management of neurotrophic keratopathy. Curr Opin Ophthalmol 1999; 10: 270-6.
3. Mackie IA. Current ocular therapy. In: Fraunfelder F, Roy FH, eds. Current Ocular Therapy, 4th edn. Philadelphia, PA: WB Saunders, 1995; 506-8.
4. Cavanagh HD, Pihlaja D, Thoft RA, Dohlman CH. The pathogenesis and treatment of persistent epithelial defects. Trans Am Acad Ophthalmol Otolaryngol 1976; 81: 754-69.
5. Groos E. Cornea: fundamentals of corneal and external disease. In: Krachmer JH, Mannis MJ, Hooland EJ, eds. Cornea: Fundamentals of Corneal and External Disease. St. Louis, MO: Mosby, 1997; 1339-62.
6. Wild S, Roglic G, Sicree R, Green A, King H. Global burden of diabetes mellitus in 2000. WHO report 2000. Available online.
7. Clark CM, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Eng J Med 1995; 332: 1210-17.
8. Aeillo LP, Gardner TW, King GL etal. Diabetic retinopathy. Diabetes Care 1998; 21: 143-56.
9. Herse PR. A review of manifestations of diabetes mellitus in the anterior eye and cornea. Am J Optom Physiol Opt 1988; 65: 224-30.
10. Feman SS. Diabetes and the eye. In: Tasman W, ed. Diabetes and the Eye, Vol. 5. Philadelphia, PA: Lippincott Williams & Wilkins, 2000; 1-10.
11. Cisarik-Fredenburg P. Discoveries in research on diabetic keratopathy. Optometry 2001; 72: 691-704.
12. Kaji Y. Prevention of diabetic keratopathy. Br J Ophthalmol 2005; 89: 254-5.
13. Schultz R, Van Horn D, Peters M, Klewin KM, Schutten WH. Diabetic keratopathy. Trans Am Ophthalmol Soc 1981; 79: 180-99.
14. Micera A, Lambiase A, Aloe L etal. Nerve growth factor involvement in the visual system: implications in allergic and neurodegenerative diseases. Cytokine Growth Factor Rev 2004; 15: 411-17.
15. Woo H-M, Bentley E, Campbell SF, Marfurt CF, Murphy CJ. Nerve growth factor and corneal wound healing in dogs. Exp Eye Res 2005; 80: 633-42.
16. Lu L, Reinach P, Kao W. Corneal epithelial wound healing. Exp Biol Med 2001; 226: 653-64.
17. Suzuki K, Saito J, Yanai R etal. Cell-matrix and cell-cell interactions during corneal epithelial wound healing. Prog Retin Eye Res 2003; 22: 113-33.
18. Chang C-Y, Green C, McGhee C, Sherwin T. Acute wound healing in the human central corneal epithelium appears to be independent of limbal stem cell influence. Invest Ophthalmol Vis Sci 2008; 49: 5279-86.
19. Nagano T, Nakamura M, Nakata K. Effects of substance P and IGF-1 in cornea epithelial barrier function and wound healing in a rat model of neurotrophic keratopathy. Invest Ophthalmol Vis Sci 2003; 44: 3810-15.
20. Maldonado B, Furcht L. Epidermal growth factor stimulates integrin mediated cell migration of cultured human corneal epithelial cells on fibronectin and arginine-glycine-aspartic acid peptide. Invest Ophthalmol Vis Sci 1995; 36: 2120-6.
21. Nishida T, Nakamura M, Mishima H, Otori T. Interleukin 6 promotes epithelial migration by a fibronectin-dependent mechanism. J Cell Physiol 1992; 153: 1-5.
22. David T, Rieck P, Renard G, Hartmann C, Courtois Y, Pouliquen Y. Corneal woun healing modulation using basic fibroblast growth factor after excimer lasephotorefractive keratectomy. Cornea 1995; 14: 227-34.
23. Saika S, Okada Y, Miyamoto T. Role of p38 MAP kinase in regulation of cell migration and proliferation in healing cornealepithelium. Invest Ophthalmol Vis Sci 2004; 45: 100-9.
24. Sharma G, He J, Bazan H. p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing. J Biol Chem 2003; 278: 21989-97.
25. Wilson SE, Walker JW, Chwang EL, He YG. Hepatocyte growth factor, keratinocyte growth factor, their receptors, fibroblast growth factor receptor-2, and the cells of the cornea. Invest Ophthalmol Vis Sci 1993; 34: 2544-61.
26. Ohji M, Mandarino L, Sundar RN, Thoft R. Corneal epithelial cell attachment with endogenous laminin and fibronectin. Invest Ophthalmol Vis Sci 1993; 34: 2487-92.
27. Maldonado B, Furcht L. Involvement of integrins with adhesion promoting, heparin-binding peptides of type IV collagen in cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci 1995; 36: 364-72.
28. Joyce NC, Zieske JD. Transforming growth factor-beta receptor expression in human cornea. Invest Ophthalmol Vis Sci 1997; 38: 1922-8.
29. Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Eng J Med 1998; 338: 1174-80.
30. Hongo M, Itoi M, Yamaguchi K, Imanishi J. Distribution of epidermal growth factor (EGF) receptors in rabbit corneal epithelial cells, keratocytes and endothelial cells, and the changes induced by transforming growth factor-beta 1. Exp Eye Res 1992; 54: 9-16.
31. Kiritoshi A, SundarRaj N, Thoft RA. Differentiation in cultured limbal epithelium as defined by keratin expression. Invest Ophthalmol Vis Sci 1991; 32: 3073-7.
32. Schultz GS, Davis JB, Eiferman RA. Growth factors and corneal epithelium. Cornea 1990; 9: 2-9.
33. Tripathi BJ, Kwait JPS, Tripathi RC. Corneal growth factors: a new generation of ophthalmic pharmaceuticals. Cornea 1990; 9: 2-9.
34. Schulze SD, Sekundo W, Kroll P. Autologous serum for the treatment of corneal epithelial abrasions in diabetic patients undergoing vitrectomy. Am J Ophthalmol 2006; 142: 207-14.
35. Gockerman A, Prevette T, Jones J, Clemmons D. Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-1 and IGF-II. Endocrinology 1995; 136: 41168-73.
36. McAvoy JW, Chamberlain CG. Growth factors in the eye. Prog Growth Factor Res 1990; 2: 29-43.
37. Nishida T, Nakamura M, Ofuji K, Reid TW, Mannis MJ, Murphy CJ. Synergistic effects of substance P with insulin-like growth factor-1 on epithelial migration of the cornea. J Cell Physiol 1996; 169: 159-66.
38. Nakamura M, Ofuji K, Chikama T, Nishida T. The NK1 receptor and its participation in the synergistic enhancement of corneal epithelial migration by substance P and insulin-like growth factor- 1. Br J Pharmacol 1997; 120: 547-52.
39. Lee H, Lee J, Kim M, Karya Y, Miyazaki K, Kim E. Insulin-like growth factor-1 induces migration and expression of laminin-5 incultutured human corneal epithelial cells. Invest Ophthalmol Vis Sci 2006; 47: 873-82.
40. Brown SM, Lamberts DW, Reid TW, Nishida T, Murphy CJ. Neurotrophic and anhidrotic keratopathy treated with substance P and insulinlike growth factor 1. Arch Ophthalmol 1997; 115: 926-7.
41. Chikamoto N, Chikama T, Yamada N, Nishida T, Ishimitsu T, Kamiya A. Efficacy of substance P and insulin-like growth factor-1 peptides for preventing postsurgical superficial punctate keratopathy in diabetic patients. Jpn J Ophthalmol 2009; 53: 464-9.
42. Yamada N, Matsuda R, Morishige N etal. Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy. Br J Ophthalmol 2008; 92: 896-900.
43. Benoliel AM, Kahn-Perles B, Imbert J, Verrando P. Insulin stimulates haptotactic migration of human epidermal keratinocytes through activation of NF-kappa B transcription factor. J Cell Sci 1987; 110: 2089-97.
44. Rosenthal SP. Acceleration of primary wound healing by insulin. Arch Surg 1968; 96: 53-5.
45. Van Ort SR, Gerber RM. Topical application of insulin in the treatment of decubitus ulcers: a pilot study. Nurs Res 1976; 25: 9-12.
46. Pierre EJ, Barrow RE, Hawkins HK. Effects of insulin on wound healing. J Trauma 1998; 44: 342-5.
47. Rocha EM, Cunha DA, Carneiro EM, Boschero AC, Saad MJ, Velloso LA. Insulin, insulin receptor and insulin-like growth factor-I receptor on the human ocular surface. Adv Exp Med Biol 2002; 506: 607-10.
48. Naeser P. Insulin receptors in human ocular tissues. Immunohistochemical demonstration in normal and diabetic eyes. Ups J Med Sci 1997; 102: 35-40.
49. Thomopoulos P, Pessac B. Insulin receptors in cultured mouse retinal cells. Diabetologia 1979; 16: 275-9.
50. Im JH, Pillion DJ, Meezan E. Comparison of insulin receptors from bovine retinal blood vessels and nonvascular retinal tissue. Invest Ophthalmol Vis Sci 1986; 27: 1681-90.
51. Zagon IS, Jenkins JB, Sassani JW etal. Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat. Diabetes 2002; 51: 3055-62.
52. Rosenberg ME, Tervo TM, Immonen IJ, Muller LJ, Gronhagen-Riska C, Vesaluoma MH. Corneal structure and sensitivity in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci 2000; 41: 2915-21.
53. Zagon IS, Sassani JW, McLaughlin PJ. Insulin treatment ameliorate impaired corneal reepithelization in diabetic rats. Diabetes 2006; 55: 1141-7.
54. Zagon IS, Klocek MS, Sassani JW, McLaughlin PJ. Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus. Arch Ophthalmol 2007; 125: 1082-8.
55. Lee YC, Simamora P, Pinsuwan S, Yalkowsky SH. Review on the systemic delivery of insulin via the ocular route. Int J Pharm 2002; 233: 1-18.
56. Chiou GC. Systemic delivery of polypeptide drugs through ocular route. Annu Rev Pharmacol Toxicol 1991; 31: 457-67.
57. Levi-Montalcini R. The nerve growth factor 35years later. Science 1987; 237: 1154-62.
58. Levi-Montalcini R, Aloe L, Alleva E. A role for nerve growth factor in nervous, endocrine and immune system. Prog Neuroendocrinimuunol 1990; 1: 1-10.
59. Lambiase A, Bonini S, Micera A, Rama P, Bonini S, Aloe L. Expression of nerve growth factors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases. Invest Ophthalmol Vis Sci 1998; 39: 1272-5.
60. You L, Kruse FE, Volcker HE. Neurotrophic factors in the human cornea. Invest Ophthalmol Vis Sci 2000; 41: 692-702.
61. Touhami A, Grueterich M, Tseng SC. The role of NGF signaling in human limbal epithelium expanded by amniotic membrane culture. Invest Ophthalmol Vis Sci 2002; 43: 987-94.
62. Ghinelli E, Johansson J, Ríos J etal. Presence and localization of neurotrophins and neurotrophin receptors in rat lacrimal gland. Invest Ophthalmol Vis Sci 2003; 44: 3352-7.
63. Ríos JD, Ghinelli E, Gu J, Hodges RR, Dartt DA. Role of neurotrophins and neurotrophin receptors in rat conjunctival goblet cell secretion and proliferation. Invest Ophthalmol Vis Sci 2007; 48: 1543-51.
64. Kruse F, Tseng S. Growth factors modulate clonal growth and differentiation of cultured rabbit limbal and corneal epithelium. Invest Ophthalmol Vis Sci 1993; 34: 1963-76.
65. Lambiase A, Bonini S, Bonini S etal. Increased plasma levels of nerve growth factor in vernal keratoconjunctivitis and relationship to conjunctival mast cells. Invest Ophthalmol Vis Sci 1995; 36: 2127-32.
66. Bonini S, Lambiase A, Rama P, Capriogli G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 2000; 107: 1347-52.
67. Sakiyama-Elbert S, Hubbell J. Controlled release of nerve growth factor from a heparin-based cell ingrowth matrix. J Control Release 2000; 69: 149-58.
68. Xie Y, Zhang X, Cui W, Lou J, Nagai T, Hou X. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. J Control Release 2005; 105: 106-19.
69. Pfister L, Alther E, Papaloizos M, Merkle H, Gander B. Controlled nerve growth factor release from multi-plyalginate/chitosan-based nerve conduits. Eur J Pharm Biopharm 2008; 69: 563-72.
70. Kanaya E, Higashizaki T, Ozawa F etal. Synthesis and secretion of human growth factor by Saccharomyces cerevisiae. Gene 1989; 83: 65-74.
71. Nishizawa M, Ozawa F, Higashizaki T, Hirai K, Hishinuma F. Biologically active humand and mouse nerve growth factors secreted by the yeast Saccharomyces cerevisiae. Appl Microbiol Biotechnol 1993; 38: 624-30.
72. Negro A, Martini I, Bigon E etal. Synthesis of the biologically active β-subunit of human nerve growth factor in Escherichia coli. Gene 1992; 110: 251-6.
73. Rattenholl A, Lilie H, Grossmann A, Stern A, Schwarz E, Rudolph R. The pro-sequence facilitates folding of human nerve growth factor from Escherichia coli inclusion bodies. Eur J Biochem 2001; 268: 3296-303.
74. Barnett J, Chow J, Nguyen B etal. Physicochemical characterization of recombinant human nerve growth factor produced in insect cells with a baculovirus vector. J Neurochem 1991; 57: 1052-61.
75. Allen SJ, Robertson AG, Tyler SJ, Wilcock GK, Dawbarn D. Recombinant human nerve growth factor for clinical trials: protein expression, purification, stability and characterisation of binding to infusion pumps. J Biochem Biophys Methods 2001; 47: 239-55.
76. Iwane M, Kitamura Y, Kaisho Y etal. Production, purification and characterization of biologically active recombinant human nerve growth factor. Biochim Biophys Res Commun 1990; 171: 116-22.
77. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002; 50: 393-413.
78. Ullrich A, Gray A, Berman C, Dull TJ. Human beta-nerve growth factor gene sequence highly homologous to that of mouse. Nature 1983; 303: 821-5.
79. Edwards RH, Selby MJ, Garcia PD, Rutter WJ. Processing of the native growth factor precursor to form biologically active nerve growth factor. J Biol Chem 1988; 263: 6810-15.
80. Shooter EM. Early days of the nerve growth factor proteins. Annu Rev Neurosci 2001; 24: 601-29.
81. Colangelo AM, Finotti N, Ceriani M etal. Recombinant human nerve growth factor with a marked activity in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102: 18658-63.
82. Li DQ, Tseng SC. Differential regulation of cytokine and receptor transcript expression in human corneal and limbal fibroblasts by epidermal growth factor, transforming growth factor-alpha, platelet derived growth factor B, and interleukin-1 beta. Invest Ophthalmol Vis Sci 1996; 37: 2068-80.
83. Hosotani H, Ohashi Y, Yamada M, Subota K. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am J Ophthalmol 1995; 119: 288-94.
84. Daniele S, Gilbard J, Schepens C. Treatment of persistent epithelial defects in neurotrophic keratitis with epidermal growth factor: a preliminary open study. Graefes Arch Clin Exp Ophthalmol 1992; 230: 314-17.
85. Jester J, Barry LP, Petroll W. Inhibition of corneal fibrosis by topical application of blocking antibodies to TGF-beta in the rabbit. Cornea 1997; 16: 177-87.
86. Mayers J, Gomes J, Siepser S. Effect of transforoming growth factor beta 1 on stromal haze following excimer laser photorefractive keratectomy in rabbits. J Refract Surg 1997; 13: 356-61.
87. Akil HS, Watson SJ, Young E, Lewis ME, Khatchaturian H, Walker JM. Endogenous opioid: biology and function. Ann Rev Neurosci 1984; 7: 223-55.
88. Zagon IS, McLaughlin PJ. The role of endogenous opioids and opioid receptors in human and animal cancers. In: Plotnikoff AJ, Murgo AJ, Faith RE, Wybran J, eds. The Role of Endogenous Opioids and Opioid Receptors in Human and Animal Cancers. Caldwell, NJ: CRC, 1991; 343-56.
89. Zagon IS, McLaughlin PJ. Opioid growth factor receptor in the developing nervous system. In: Zagon IS, McLaughlin PJ, eds. Opioid Growth Factor Receptor in the Developing Nervous System, Vol. 1. London: Chapman and Hall, 1993; 39-62.
90. Zagon IS, McLaughlin PJ. Identification of opioid peptides regulating proliferation of neurons and glia in the developing nervous system. Brain Res 1991; 542: 318-23.
91. Meriney SD, For MJ, Oliva D, Pilar G. Endogenous opioids modulate neural survival in the developing avian ciliary ganglion. J Neurosci 1991; 11: 3705-17.
92. Zagon IS, Isayama T, McLaughlin PJ. Preproenkephalin mRNA expressionin the developing and adult rat brain. Mol Brain Res 1994; 21: 85-98.
93. Zagon IS, McLaughlin PJ. Production and characterisation of polyclonal and monoclonal antibodies to the zeta (ζ) opioid receptor. Brain Res 1993; 630: 295-301.
94. McLaughlin PJ. Opioid antagonist modulation of rat heart development. Life Sci 1994; 54: 1423-31.
95. Zagon IS, Wu Y, McLaughlin PJ. Opioid growth factor (OGF) inhibits DNA synthesis in mouse tongue epithelium in a circadian-dependent manner. Am J Ophthalmol 1994; 267: R645-52. (Regulatory Integrative Comp. Physiol. 36).
96. Tinsley PW, Dass C, Trimble JW, Desiderio DM. Identification of methionine enkephalin in the bovine by fast atom bombardment-mass spectrometry. Exp Eye Res 1990; 51: 671-4.
97. Tinsley PW, Fridland GH, Killmar JT, Desiderio DM. Purification, characterization, and localization of neuropeptides in the cornea. Peptides 1989; 9: 1373-9.
98. Zagon IS, Sassani JW, McLaughlin PJ. Opioid growth factor modulates corneal epithelial outgrowth in tissue culture. Am J Physiol 1995; 268: R942-50.
99. McLaughlin PJ, Sassani JW, Klocek MS, Zagon IS. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review. Brain Res Bull 2010; 81: 236-47.
100. Cheng F, McLaughlin PJ, Banks WA, Zagon IS. Passive diffusion of naltrexone into human and animal cells and upregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol 2009; 297: R844-52.
101. Zagon IS, Sassani JW, McLaughlin PJ. Reepithelialization of the human cornea is regulated by endogenous opioids. Invest Ophthalmol Vis Sci 2000; 41: 73-81.
102. Zagon IS, Sassani JW, McLaughlin PJ. Re-epithelialization of the rat cornea is accelerated by blockade of opioid receptors. Brain Res 1998; 798: 254-60.
103. Zagon IS, Sassani JW, McLaughlin PJ. Re-epithelialization of the rabbit cornea is regulated by opioid growth factor. Brain Res 1998; 803: 61-8.
104. Klocek MS, Sassani JW, McLaughlin PJ, Zagon IS. Topically applied naltrexone restores corneal reepithelialization in diabetic rats. J Ocul Pharmacol Ther 2007; 23: 89-102.
105. Klocek MS, Sassani JW, McLaughlin PJ, Zagon IS. Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats. Exp Eye Res 2009; 89: 686-92.
106. Zagon IS, Klocek MS, Sassani JW, McLaughlin PJ. Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus. Arch Ophthalmol 2009; 127: 1468-73.
107. Zagon IS, Klocek MS, Sassani JW, Mauger DT, McLaughlin PJ. Corneal safety of topically applied naltrexone. J Ocul Pharmacol Ther 2006; 22: 377-87.
108. Zagon IS, Sassani JW, Malefyt KJ, McLaughlin PJ. Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Arch Ophthalmol 2006; 124: 1620-4.
109. Yamada M, Ogata M, Kawai M, Mashima Y. Decreased substance P concentrations in tears from patients with corneal hypesthesia. Am J Ophthalmol 2000; 129: 671-2.
110. Kingsley RE, Marfurt CF. Topical substance P and corneal epithelial wound closure in the rabbit. Invest Ophthalmol Vis Sci 1997; 38: 388-95.
111. Ohashi Y, Matsuda M, Hosotani H. Aldose reductase inhibitor(CT-112) eye drops for diabetic corneal epitheliopathy. Am J Ophthalmol 1988; 105: 233-8.
112. Yokoi N, Niiya A, Komuro A. Effects of aldose reductase inhibitor, CT-112, on the corneal epithelial barrier of galactose-fed rats. Curr Eye Res 1997; 16: 595-9.
113. Nishio T, Sunohara N, Furukawa S, Akiguchi I, Kudo Y. Repeated injections of nicergoline increase the nerve growth factor level in the aged rat brain. Jpn J Pharmacol 1998; 76: 321-3.
114. Giardino L, Giuliani A, Battaglia A, Carfagna N, Aloe L, Calza L. Neuroprotection and aging of the cholinergic system: a role for the ergoline derivative nicergoline (Sermion). Neuroscience 2002; 109: 487-97.
115. Kim S-Y, Choi J-S, Joo C-K. Effects of nicergoline on corneal epithelial wound healing in rat eyes. Invest Ophthalmol Vis Sci 2009; 50: 621-5.
116. Bartlett JD, Slusser TG, Turner-Henson A, Singh KP, Atchison JA, Pillion DJ. Toxicity of insulin administered chronically to human eye in vivo. J Ocul Pharmacol 1994; 10: 101-7.
117. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 1996; 19: 514-20.
118. Levi-Montalcini R, Dal Toso R, Valle FD, Skaper SD, Leon A. Update of the NGF saga. J Neurol Sci 1995; 130: 119-27.
119. Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol 2007; 12: 505-23.